News

Boltz raises $110 million Series A for biomolecular AI

Boltz raised a $110 million Series A led by Bessemer Venture Partners to expand compute, data resources and hiring for its biomolecular AI platform.

D
Nov 19, 2026 · 2 min read

Boltz raised a $110 million Series A led by Bessemer Venture Partners, the biomolecular AI company announced on November 18. It plans to use the financing for more compute and data, to meet demand from partners and to expand its team.

The company did not say how much it will spend on each of those priorities. Neither Boltz nor Bessemer’s announcement confirming the round disclosed a valuation, dilution, security terms, closing date, individual investor contributions, board rights or an expected cash runway.

Existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures participated, according to Boltz. The company also named Greycroft, F-Prime Capital, Hummingbird and Benchling among its new investors.

Boltz develops models intended to help pharmaceutical researchers design small molecules and proteins. The company said molecular-token volume processed for paying customers grew 50-fold from a June 16 baseline through November 8. The figure comes from a company chart and was not independently audited in the supplied evidence. Bessemer cited more than 5 million model downloads and use by more than 100,000 scientists, but the supplied evidence did not independently verify either adoption figure.

Boltz said it works with six of the world’s 20 largest pharmaceutical companies, although it named only four in the financing announcement. Separate official announcements document arrangements with Pfizer, Takeda, GSK and Bristol Myers Squibb. The other two claimed partners were not identified.

Boltz has also published performance claims for its models. The company said BoltzMol-1 found confirmed hits on six of 10 tested targets, while BoltzProt-1 nearly tripled the de novo nanobody hit rate over an earlier model, BoltzGen. It also said its small-molecule workflow can move from a target to validated hits in three to eight weeks on a $10,000 to $15,000 compute-and-validation budget. Those results and comparisons were not independently replicated in the supplied evidence.

Moving from a therapeutic hypothesis to a human-ready molecule entirely through computation remains a long-term goal for Boltz, not a demonstrated capability. The company said reaching it will require further model advances and substantial investment in compute and data.

More news